Compare Boston Beer Company Inc (SAM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs BIO-TECHNE Corp — how do they compare? Boston Beer Company Inc trades at $163.71 (market cap $1.67B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is far larger — about 6.8× Boston Beer Company Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| SAM | TECH | |
|---|---|---|
Market Cap | $1.67B | $11.34B |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $72.48 |
52-Week Low | $161.08 | $43.31 |
Enterprise Value | $1.43B | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Boston Beer Company (SAM) trades at $162.06, down 3.98% today, showing mixed signals with bearish technical indicators but positive cash flow trends. Recent earnings have missed expectations in Q1 and Q2 2026, though Q4 2025 beat estimates. The company maintains a debt-free balance sheet with strong operating cash flow of $270M in 2025, but faces volume declines and margin pressure.
SAM presents a cautious outlook with analyst consensus leaning Hold (71.87%) despite a $207.33 price target suggesting 28% upside. Key risks include declining alcohol consumption and execution challenges, while opportunities lie in new product launches and marketing leadership changes. The stock's valuation appears reasonable with P/E of 22.66 and P/S of 0.89.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
